AstraZeneca PLC AZN announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending the marketing approval for ...
PRINCETON, N.J. and LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYS: BMY) and AstraZeneca (NYS: AZN) today announced that the European Commission has approved Forxiga ™ (dapagliflozin) ...
AstraZeneca and Bristol-Myers Squibb Company today announced that the European Commission has approved FORXIGA™ (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union (EU).
Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes Forxiga, a once-daily oral agent, provides ...
(RTTNews) - AstraZeneca Plc (AZN.L, AZN) announced the company's Forxiga has been approved in Japan for the treatment of patients with chronic heart failure who are receiving standard of care. The ...
Forxiga ™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes Forxiga, a once-daily oral agent, provides ...
Forxiga, a once-daily oral agent, provides physicians with a new option to improve glycaemic control as monotherapy in metformin-intolerant patients or combination therapy Reduction of weight and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback